Financing rounds: Tilak Healthcare, Exosystems, Augury, DNA Script, Egle Therapeutics

France: Egle Therapeutics, an emerging biotechnology company focused on developing immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases, has completed a €40m (US$46.4m) Series A financing. The financing round was co-led by LSP and Bpifrance through their InnoBio 2 fund. Fund+, Bioqube Ventures and Takeda Ventures also participated. Proceeds will be…

You must be a HMI Subscriber to view this content.

Subscribe Now »